Practical value of MIB-1 index in predicting behavior of astrocytomas

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 3, 2011, Pages 520-525

  Ambroise, M Moses ^a   Khosla, Charu ^b   Ghosh, Mitra ^a   Mallikarjuna, V ^a   Annapurneswari, S ^a  

^a APOLLO HOSPITALS   (India)

^b FATHER MULLER MEDICAL COLLEGE   (India)

Author keywords

Astrocytomas; Ki 67; MIB 1 LI; prognostic value

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGE DISTRIBUTION; ANTIBODY LABELING; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIB 1 LABELING INDEX; PILOCYTIC ASTROCYTOMA; PROGNOSIS; SEX DIFFERENCE;

ADOLESCENT; ADULT; ASTROCYTOMA; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 80053918320     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.85085     Document Type: Article

References (30)

1. Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1992;168:85-6.
2. Scholzen T, Gerdes J. The Ki-67 prote From the known and the unknown. J Cell Physiol 2000;182:311-22.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. World Health Organization of tumors of the central nervous system. Lyon: IARC; 2007.
4. Matsumoto T, Fujii T, Yabe M, Oka K, Hoshi T, Sato K. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Histopathology 1998;33:446-52.
5. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999;58:46-53.
6. Roessler K, Bertalanffy A, Jezan H, Ba-Ssalamah A, Slavc I, Czech T, et al. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas. J Neurooncol 2002;58:141-6.
7. Ralte AM, Sharma MC, Karak AK, Mehta VS, Sarkar C. Clinicopathological features, MIB-1 labeling index and Apoptotic index in recurrent Astrocytic tumors. Pathol Oncol Res 2001;7:267-78.
8. Tihan T, Davis R, Elowitz E, DiCostanzo D, Moll U. Practical Value of Ki-67 and p53 Labeling Indexes in Stereotactic Biopsies of Diffuse and Pilocytic Astrocytomas. Arch Pathol Lab Med 2000;124:108-13.
9. Bowers DC, Gargan L, Kapur P, Reisch JS, Mulne AF, Shapiro KN, et al. Study of the MIB-1 Labeling Index as a Predictor of Tumor Progression in Pilocytic Astrocytomas in Children and Adolescents. J Clin Oncol 2003;21:2968-73.
10. Haapasalo H, Sallinen S, Sallinen P, Helén P, Jaaskelainen J, Salmi TT, et al. Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas. Neuropathol Appl Neurobiol 1999;25:134-42.
11. Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR. Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol 2009;117:657-65.
12. Klein R, Roggendorf W. Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: A double labeling study. Acta Neuropathol 2001;101:245-8.
13. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;7:373-80.
14. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1(Ki-67) immunoreactivity in differentiating grade II and grade III Gliomas. J Neuropathol Exp Neurol 1997;56:857-65.
15. Rathi KR, Radotra BD, Khosla VK. Proliferative index in astrocytic tumours. Indian J Pathol Microbiol 2007;50:754-8.
16. Rodriguez-Pereira C, Suárez-Penaranda JM, Vázquez-Salvado M, Sobrido MJ, Abraldes M, Barros F, et al. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. J Neurosurg Sci 2000;44:203-10.
17. Johannessen AL, Torp SH. The Clinical value of Ki-67/MIB-1 Labeling Index in Human Astrocytomas. Pathol Oncol Res 2006;12:143-7
18. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 1992;66:373-85.
19. Neder L, Colli BO, Machado HR, Carlotti CG Jr, Santos AC, Chimelli L. MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol 2004;23:262-70.
20. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997;56:798-805.
21. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: An immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatr 1995;59:413-9.
22. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB- 1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 1998;57:931-6.
23. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 1998;42:724-9.
24. Avninder S, Sharma MC, Deb P, Mehta VS, Karak AK, Mahapatra AK, et al. Gemistocytic astrocytomas: Histomorphology, proliferative potential and genetic alterations-a study of 32 cases. J Neurooncol 2006;78:123-7.
25. Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, et al. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999;86:672-83.
26. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 2002;58:203-15.
27. Ribeiro Mde C, Coutinho LM, Hilbig A. The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis. Arq Neuropsiquiatr 2004;62:262-70.
28. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella- Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998;24:381-8.
29. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 2006;76:193-200.
30. Grzybicki DM, Liu Y, Moore SA, Brown HG, Silverman JF, D'Amico F, et al. Interobserver Variability Associated with the MIB-1Labeling Index. Cancer 2001;92:2720-6.